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Cancer is caused by an uncontrolled cell division, forming a tumor capable of 
metastasis. Cancer is the second leading cause of death worldwide. Conventional 
treatments kill healthy cells, causing side effects. Recently, nanomaterials are 
explored due to properties such as as- nano-size, high loading, and ligands’ attach-
ment for a selective delivery. Apart from normal body cells, cancer cells express 
many receptors in excess, which serve as ‘targets’ for attacking the cells. Various 
ligands like proteins, peptides, polysaccharides can be attached to nanoparticles 
to allow proper and specific reach to the tumor. Such nanoparticles go to their 
desired site and stick onto the receptors, taken inside the cells by various methods. 
Antibodies are natural proteins that bind to foreign substances and remove them. 
IgG being the most explored antibody, suffers from many disadvantages such as 
non-specificity for required antigen, limited binding sites, low tumor penetration. 
Hence many researchers experimented by removing and adjusting the binding sites, 
using only the binding sites, enhancing the valency of naturally available IgG. It 
gave many benefits such as enhanced penetration, reduced immunogenicity, better 
delivery of drugs with fewer side effects. Continuing advancements in the field 
of protein engineering will help scientists to come up with better solutions. The 
properties allow easy surface interaction and entry, achieve better biodistribution, 
and reduce the amount of drug required. Targeting is based on Paul Ehrlich’s ‘magic 
bullet, ‘where the therapeutic moiety has two parts-one to identify the target and 
the second to eliminate it. This concept is revised to incorporate a third component, 
a carrier. Many nanocarriers can be used to target cancer cells containing ligands 
to identify malignant cells. Approaches to targeting are passive, active and physical 
targeting. Many such nanoparticles are in clinical trials and can be a better solution 
to cancer therapy.
Keywords: nanoparticles, cancer immunotherapy, targeted drug delivery, cancer, 
targeting, nanomedicine, antibody fragments
1. Introduction
For the innovative treatment of cancer, it is necessary to boost target-based 
cancer therapy, ensuring that it could differentiate between normal and cancer cells 
while targeting cells [1]. Targeted cancer therapies are far better than the conven-
tional method [2]. Therefore, targeted cancer therapy enjoys lesser unwanted side 
effects and an excellent molecular mechanism, which promotes minimum toxicity 
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caused by chemotherapeutic drugs [3]. The rapid clearance from the body can be 
seen when the drug was administered in a higher tolerable dose, which ultimately 
leads to higher toxicity [4]. During targeted therapy, the drug could be modi-
fied to target biological transduction pathways and cellular factors. It also targets 
angiogenesis and apoptosis inducing molecules [5]. In recent years, several studies 
have been designed to investigate the effects of nanosized medicines inoperative 
targeting and diagnosis of cancer cells. Nanoparticles can possibly entrench drugs, 
theranostic agents, and genes [6]. It was also observed from the various research 
findings that, nanoparticular approach while drug targeting improves drug toler-
ability and bioavailability [7]. In formulation drug delivery, anchoring, fabricating, 
protection of payload from getting degradation by enzymes are possible [8]. The 
anchored nanoparticles can able to deliver a higher dose into tumor cells while 
bypassing the normal cells. The modified scaffold integration of nanoparticles 
facilitates biodistribution of specific drug delivery, which conjugates with ligands 
and eventually binds with tumor biomarkers [9]. Paul Ehrlich recently suggested a 
magic bullet, where two different targetings are possible with consistent therapeu-
tic action [10]. In recent research articles and patents, it was often observed that 
many pharmaceutical carriers such as liposomes, micelles, polymeric nanoparticles 
designed from natural or synthetic sources were used to target chemotherapeutic 
medicaments in different cancer cells [11]. Many nanoparticles have passed phase 
II of the clinical trials stage. This suggests that effective active and passive targeting 
is possible, due to which greater specificity while selecting cancer target is achieved 
[12]. Nowadays, conjugation of antibodies, peptides, small chemical entities are 
versatile in delivering anticancer agents in the form of nanoparticle composite [13]. 
However, tumor targeting is not an easy job! Scientists are targeting tumors in three 
different mechanisms; (a) Where nanoparticles were pre-exposed with leaky vas-
culature of tumor cells and encountered with the reticuloendothelial system (RES) 
or enhanced permeability and retention (EPR) effects [14]. However, (b) active 
targeting is more advantageous, as inactive targeting, uncontrolled cell prolifera-
tive targeting of tumors, and pH and temperature-dependent targeting is possible. 
In physical targeting (c) pathological conditions such as pH and temperature play 
a key role. Nevertheless, targeting the tumor side also depends on the size of the 
nanoparticles. The nanoparticles, which are less than 7 nm, come under hydrody-
namic diameters, easily passing through renal excretion [15]. The nanoparticles that 
are larger than 100 nm are eventually cleared from the circulation by the phagocytic 
system [16]. The nanoparticles’ surface charge also plays a pivotal role, as the 
particles’ cationic charge helps to facilitate internalization [17]. Sometimes surface 
addition of poly (sarcosine) and poly (ethylene glycol) [18] enhances the circulating 
half-life of the particles, on the other hand, preventing nanoparticles from getting 
engulfed by the reticuloendothelial system; by which accumulation of a certain 
amount of nanoparticles on the outer surface of the cancerous tissue is possible. To 
make nanoparticles more advanced, hooking ligands onto the nanoparticles’ body 
facilitates internalization into cancer cells.
2. Molecular targets in cancer
To target cancerous cells, it is essential to target molecular aberrations. Effective 
nanoparticular therapy for cancer targeting relies on the ability to targets such 
genetic alterations to provide significant clinical benefits [19]. Nowadays, scientists 
are more focused on targeting p53, ALK PIK3CA, KRAS, G-NAQ, MET, BRAF, 
EGFR, CKIT genes, and certain pathways, i.e., PI3K/Akt/mTOR, etc. [20].
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3. Ligands for cancer targeting
Ligands are a prerequisite for cancer. Recently, immunotoxin has obtained 
clinical approval from USFDA, and more than 100 ligand-targeted therapies are 
under clinical trials [21]. Newly developed phase-display techniques allow selec-
tive targeting with higher affinity. The bispecific antibodies and fusion proteins 
have been used for therapeutic purposes. Mostly the nanoreservior systems viz., 
niosomes, and polymeric nanoparticles are most suitable for ligand-based targeting 
[22]. However, pharmacokinetic behaviors and bio-distribution understanding of 
the molecules are still unknown. The principles of Ligands for cancer targeting can 
also be applied to the targeted delivery of gene medicines such as antisense oligo-
nucleotides [23].
4. Attachment of ligands to carriers
Most of the nanoparticles as specially lipid-based formulations and polymeric 
nanoparticles are emerging as the best carrier system to deliver the molecule in 
cancerous tissues [24]. Monoclonal antibodies and peptides are possibly the best 
carriers. The surface-bound ligands specifically bind to the target cells. The vari-
ous techniques viz., covalent and non-covalent techniques help in effective active 
targeting of cancer cells (Figure 1).
5. Receptor approaches of drug targeting in cancer
Receptor based targeting is being focused on ensuring the accurate delivery 
of carriers to their desired location [25]. It allows targeting not only to a localized 
tumor but also to traveling cancerous cells. This ensures precise delivery. Due to the 
excessive expression of receptors, targeting becomes easy. Ligands carry out the 
functionality through active targeting [26].
Figure 1. 
Due to the active targeting, the nanoparticles are getting accumulated in the tumor site. Compered to non-
targeted nanoparticles, actively targeted nanoparticles reach the tumor site with higher efficiency and through 
the endocytosis process, the nanocomposite triggers cancer cells death.
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Receptor based targeting is being focused on ensuring the accurate deliv-
ery of carriers to their desired location [25]. It allows targeting not only to 
a localized tumor but also to traveling cancerous cells. This ensures precise 
delivery. Due to the excessive expression of receptors, targeting becomes easy. 




EGFR is a glycoprotein spanning across cell membranes. It is a target for 
Epidermal Growth Factor [28]. It initiates a signaling pathway leading to cell prolif-
eration and mitosis. This is overexpressed in breast, colon, head and neck, ovarian 
tumors, and renal and glioma. The binding of antibodies against this receptor 
reduces cell proliferation. Many researchers prepared drug-loaded vesicles to target 
EFGR, which increased the drug’s efficacy more than 10-fold [29]. Recently, cancer 
varieties like colorectal, lung, head, and neck carcinoma showed resistance to EGFR 
targeting due to mutations in the gene causing inhibition of activation and hence 
signaling.
6.2 Interleukin receptors
As interleukin receptors are majorly expressed, they are essential as a target for 
delivery. Among many varieties, types-3, 4, 6, 11, 13 & 16 were investigated as a tar-
get. The complex of ligand and receptor is taken inside the cell and hence helps cell 
growth and proliferation. But an overexpression may cause resistance to apoptosis 





IL-4 Glioblastoma, ovarian cancer, lung cancer, breast cancer
IL-3 Chronic Myelogenous leukemia, acute myeloid leukemia blast
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Various researchers used many ways to target IL receptors and obtained posi-
tive results such as reduced proliferation, enhanced uptake of carriers, decreased 
tumor volume, as well as accumulation and entry into the tumor as well as increased 
survival. This is not a full-proof strategy as blocking signaling of one type may be 
compensated with another type. And if the interleukins are blocked, it hinders the 
functioning of the immune system.
6.3 Folate receptors
Folate receptor is a glycoprotein present on the external cell surface. It is rich in 
cystine content. It has three subtypes- α, β and γ [30]. It is responsible for the entry 
of folic acid into cell, which is important for nucleic acid synthesis. The α subtype 
is overexpressed in breast, lung, colon cancer, and mesothelioma [31]. According 
to studies from many researchers, positive results such as a reduced tumor volume, 
nuclear delivery of therapeutic moieties, increased survival of cells, upregulation 
of cell death were observed. As folate receptors are present in the body on abundant 
sites, the selectivity may not always be achieved. Also, there are no animal models 
for therapeutic advantages or toxicity profiling.
6.4 Integrin receptors
Integrins are proteins that bind to the extracellular matrix and promote cell 
binding to tissues. Due to this action, this receptor is essential in the progression 
and metastasis of tumors. ‘RGD motif ’ is a polypeptide chain important for bind-
ing and has been majorly exploited as a drug target [32]. Targeting the RGD motif 
has advantages such as improved survival, reduced tumor mass, and tumor growth 
inhibition. A major drawback of integrin targeting is diseases such as progressing 
lymphadenopathy [33].
7. Receptors to inhibit metastasis
7.1 The cluster of differentiation receptors
CD receptors initiate tumor development and can self-renew, overexpression of 
ABC, dormant. These features give tumor characteristics such as resistance, recur-
rence, and metastasis. Blocking these receptors prevents metastasis. CD subtypes 
14, 22, 36, 44, 133 have been explored as drug targets for delivery. Targeting CD-44 
receptors on cells allowed delivery into even the resistant tumors and showed 
enhanced cytotoxicity [34].
8.2 Estrogen receptors
These are nuclear receptors binding to the hormone estrogen. Estradiol acts as 
a transcription factor and controls cell growth. Estrogen helps in the development 
of sexual and reproductive functions, initiation and forming of lungs, mammary 
glands, and prostate gland. These receptors are excessively expressed in the major-
ity of types of breast cancers, making it an ideal target. Initially, hormone analogs 
were used as ligands to target, but the binding strength was not optimal due to the 
modified structure of hormones. Also, another drawback was excessive RES uptake 
of such liposomes, which was overcome by formulating stealth liposomes. These 
formulations showed reduced tumor volume [35].
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8. Targets for resistant tumors
8.1 Transferrin receptor
It is a receptor present on the cell membrane which is responsible for obtaining 
iron inside the cell. Iron binds to transferrin, and this complex binds to the receptor, 
which is then internalized [36]. Iron is necessary for many functions, such as DNA 
synthesis. This receptor can be targeted even if the tumor is Multi-drug resistant. 
Targeting this receptor has shown excellent results in resistant tumors such as 
increased formulation internalization, reduced drug required, higher cell death, 
and enhanced cytotoxicity [37]. This receptor’s drawback is its presence at non-
malignant sites such as endocrine glands may cause a loss in efficacy.
8.2 HER2
Human epidermal growth factor receptor-2 (HER-2) is a receptor spanning 
across the cell membrane with having a protein kinase internal subunit [38]. It is 
excessively expressed in gastric, lung, breast, and ovarian cancers. Overexpression 
of this receptor makes it challenging to forecast carcinoma. But, commercial 
products such as Herceptin have shown a promise targeting this receptor [39]. 
Targeting the HER-2 may help in cases of tumors showing resistance. This type of 
targeting has also demonstrated reduced cancer cell viability, enhanced cytotoxicity 
in resistant tumors, and increased uptake in the studies. A significant drawback is 
the absence of any natural ligand for the HER-2 receptor, which makes targeting 
difficult [39].
8.3 Antibodies for targeting cancer
Cancer cells are derived from normal body cells; hence they have a similar recep-
tor constitution on the cell surface. Due to this lack of specialized markers, chemo-
therapeutic agents cannot differentiate between normal and cancer cells. Hence, 
they show toxicity. Keeping a low dose may result in resistance [40]. Therefore to 
achieve a specific targeting, antibodies specific for antigens presented by cancer 
cells can be targeted.
8.4 Engineering of antibodies
IgG is the majorly used antibody for targeting cancer [41]. Antibodies have ‘Y’ 
shaped structures where two arms have the sites for antigen binding. Monoclonal 
antibodies which are derived from a single clone of cells themselves or only the 
targeting fragments, can be used for cancer therapy. These agents bind the antigen 
and cause cell death by antibody-dependent toxicity, complement activation, or 
blocking signal transduction inside the cell. The antibody has a high affinity for 
its specific antigen and has excellent binding strength due to the presence of two 
binding sites. Entire antibodies may cause activation of the immune system inside 
the body. And due to their long half-lives, detection also becomes an issue. Using 
antibodies from species other than humans may cause severe allergic reactions. 
Hence to combat this situation, researchers have developed various molecules based 
on antibodies. Antibodies have been developed where binding sites from mouse 
have been attached to human antibody (chimeric antibody), humanized or human 
antibodies have also been developed. Researchers have separated the Fc fragments 
responsible for binding and have used them for targeting.
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9. Effector mechanism of antibodies
Antibodies usually target antigens that are unique to cancer cells or which are 
excessively expressed on the cell surface. The majority of antibodies induce cancer 
cell death by binding to their target receptor, either blocking the receptor or chang-
ing the receptor’s activation requirements [42]. They disturb signaling pathways 
responsible for cell growth and survival; hence, they end up killing the cells [43]. 
For example, Cetuximab is an antibody directed against EGFR. Epidermal growth 
factor upon binding to EFGR causes tumor growth, proliferation, and migration. 
EFGR is seen in many cancers. Cetuximab binds to EGFR and blocks the recep-
tor hence preventing ligand binding and subsequent receptor dimerization. This 
process leads to apoptosis. Human epidermal growth factor receptor 2 is a member 
of the tyrosine kinase family. It is overexpressed in breast and ovarian cancers. The 
unique feature of this receptor is the absence of any known natural ligand. Instead, 
it forms dimers with other growth factor receptors and exerts its effects. Hence 
antibodies that are made to target this receptor prevent its dimerization with any 
other receptor and prevent survival.
Indirect action of antibodies involves host immune system participation and 
causes cytotoxicity by activation of complement system, antibody-dependent 
phagocytosis, and antibody-dependent cytotoxicity. Most antibodies are able 
to activate the complement system, which targets and destroys the cancer cell. 
Ofatumumab, an anti-CD20 antibody, intensifies the process of cytotoxicity 
through complement activation. Antibody-dependent phagocytosis occurs after a 
cancer cell opsonized by mAb attaches to a macrophage FcyRI glycoprotein. Then 
macrophage consumes such a marked cell [44].
10. Resistance to mAb
Even if mAb therapy is successful, many patients show resistance to it. The 
resistance may be innate or acquired after exposure to antibodies. Natural resistance 
is already present in mutations in cancer cells prior to the therapy, and acquired 
resistance is received after the exposure to therapy [45]. Another limitation is 
the dependency of the therapy on the overexpression of receptors. Mutations of 
receptors and the components in the signaling pathway may decrease the efficacy 
of antibody-targeted therapy. If cells express a variant of the receptor, therapy’s 
potency may still decrease even if the binding site does not change [46].
11. Antibody fragments
Advancement in protein sciences has enabled scientists to produce antibody 
fragments with a smaller size but the same efficacy. The ideal characteristics of an 
antibody fragment are discussed in Figure 2.
In the beginning, proteolysis was the method of choice to produce smaller 
antibody fragments [47]. These fragments had a molecular weight of around 
54 kDa–100 kDa (Fab, Fab2). In the later stages, recombinant DNA technology was 
used to prepare univalent and bivalent fragments which had heavy and light chains 
of a variable section of antibody [48]. Such a structure was the smallest targeting 
unit to be generated. The two chains were joined with a flexible polypeptide linkage 
giving a ‘single chain variable fragment’ (scFv). It was convenient to use because of 
its small size and easy production.
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In the 1980s, researchers isolated and screened a heavy chain of the murine 
antibody for its binding to lysosomes [49]. It was called a single domain antibody’ 
(dAb) as it contained only a heavy or light chain and had a meager molecular weight 
(15 kDa). However, it had drawbacks like poor solubility and aggregation, and a 
major issue was that the fragments did not retain the original’s binding efficacy 
[49]. Components from animals such as camels, llamas, and fish such as sharks were 
used as more soluble, but they suffered from immunogenicity issues. Efforts like 
immunization and bioengineering to reduce agglomeration were carried out for 
effective use in therapy [50].
Later the above types were converted from univalent to multivalent through 
protein engineering, which was then used to target multiple entities at once [51]. 
These multivalent fragments show slower dissociation from the receptor and high 
functionality. One great example of multivalent fragments is a ‘diabody’ formed by 
linking light and heavy chain by a single chain variable fragment to be self-assem-
bled into a dimer [52]. Diabodies have an advantage such as moderate molecular 
weight, multivalency which give them characteristics like improved penetration in 
tissue, rapid clearance. These diabodies bind to tumor antigen as well as to CD3 cells 
to kill tumors through T-cell mediated toxicity. The mini body is another type of 
synthesized antibody fragment, which is a pair of single chains of variable frag-
ments interconnected by-CH3 bonds, and a variable region specific for any antigen 
is attached to this pair. Minibodies are more suitable for targeted radiotherapy 
because they show better uptake and are cleared faster as compared to other types 
of fragments and are cleared rapidly. In the structure of the Mini body, the single 
variable region can be replaced by a cytotoxic agent, radioisotope, for its delivery.
Nanobody is the shortest antibody fragment. It is isolated from camelid heavy 
chains of variable antibody region. It is produced by making phage viral coat 
cover the desired fragment. As these antibodies do not have light chains, they are 
structurally different than normal antibodies. They have a concave antigen-binding 
region larger than other antibodies. Hydrophilic structures replace the usual 
hydrophobic amino acid residue. Such adjustments allow antigen-binding property 
even in the absence of light region. Another specific property is its ability to cross 
blood–brain barrier.
Figure 2. 
Different characteristics of antibody fragments.
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12. Application of fragments in imaging
12.1 Cancer imaging
Antibodies that bind to the target can be coupled with a radionuclide, fluores-
cent molecules to obtain images of cancer. Antibodies that have longer half-life 
need more time for imaging and may blur the image. These fragments have a short 
half-life and higher permeability, which allow easy detection. Techniques such as 
Positron emission tomography (PET), Computed tomography (CT), Single-photon 
emission computed tomography (SPECT) are now being performed where the 
antibody fragments are employed [53].
12.2 Nuclear imaging
Nuclear imaging is essential for the detection of cancer. Using fragments reduces 
nuclear exposure to radiation. The bifunctional connector connects antibody frag-
ment and radionuclide, and such complexity easily accumulates at the tumor and 
gives clear visualization [54]. This method can be used to measure the absorption 
of drugs and the expression of receptors. One issue with the complex is increased 
radiation in the kidney due to complex breakdown and retention of radionuclide in 
the kidney [37].
12.3 Dual modality imaging
It involves non-invasive assessment of disease and fluorescence imaging of 
tumors during surgery. This technique shows accurate and reliable results [55]. 
Heterodimeric antibodies are used to target two issues at once and have a stronger 
affinity than homodimer.
12.4 Other imaging
Antibody fragments can be coupled with microbubbles, and it enhances the tar-
geting efficiency [56]. Photoacoustic imaging also can be performed with antibody 
fragments to give high-resolution images. The laser causes expansion of tissues, and 
it produces sound waves, which later can be converted to images by the ultrasonic 
transducer.
13. Application in cancer therapy
13.1 Intrinsic therapeutic effect
The selection of antigen is most important for targeting. The target antigen is 
highly expressed in cancer cells but not on a normal cell. Single, as well as multiple 
targeting, can be achieved through the use of an engineered antibody. Multivalent 
antibodies not only block signaling but also overcome resistance through multiple 
targets [57].
13.2 Targeted drug delivery
The delivery of anti-tumor drugs using antibody fragments is a common 
practice of targeting medicine to the tumor [58]. Such systems ensure accurate 
delivery and improve the pharmacokinetics of agents. Effector molecules such 
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as siRNA cannot target and have very low uptake. Coupling them with antibod-
ies shows enhanced tumor uptake and reduced side effects [59]. An example is 
CXC chemokine receptor siRNA delivered by coupling with anti-HER2 peptide 
fusion protein e23sFv-9R is used to target breast cancer cells, having an excess of 
HER-2 receptors, which promotes apoptosis. Immunotoxins also can be targeted 
for effective therapy. Immunotoxins from plants and animals may show a rapid 
immunogenicity and have toxic side effects that may be harmful to humans. For 
example, an immunotoxin was synthesized by a combination of Pseudomonas 
aeruginosa exotoxin and short-chain variable fragment, which reduced tumor cells’ 
reduced survival and improved the survival rate. An antibody fragment can also be 
attached to nanoparticles, which then enter the tumor cells via receptor-mediated 
endocytosis. An example is the anti-HER-2 short-chain variable fragment attached 
to the PEG-coated iron oxide particle, which shows a better targeting and improved 
serum half-life.
13.3 Application in immunotherapy
Tumor cells have barriers to protect them from the body’s immune system, such 
as an impenetrable stroma and immunosuppressive cells in the tumor environment 
[60]. Tumor cells block antigen overexpression and increase regulatory-T cells 
and hence escape the immune system of the body. Immunotherapy overturns this 
mechanism and brings about the death of cancer cells. Bispecific antibodies can 
target two antigens at once, including an antigen on the cancer cell and a receptor 
on the cell of the immune system. Then the proteins in cell death signaling are 
activated by phosphorylation, which then initiates apoptosis. Bispecific antibodies 
link two cells hence bypassing innate as well as acquired resistance.
Chimeric antigen receptor on T cells (CAR-T) is being focused on as a target of 
antibodies as it helps in specific recognition of cancer cells [61]. Upon activation, it 
shows a high amount of cytokine release, which then kills cancer cells. This also can 
help to circumvent tumor resistance for killer T-cells.
For immunotherapy, a specific target is required for the immune system to 
attack or else; there can be severe side effects related to immunity. Also, the extent 
of immune response should also be considered for the efficacy of the treatment. An 
immune response, which is too low may not be able to kill the malignant cells, and a 
very strong immune response may cause cytokine storms and harm the healthy cells 
instead.
14. Antibody derivatives
IgG is the most explored antibody of choice for cancer targeting. Antigen bind-
ing if is the desired mechanism; only antigen-binding fragment can be separated 
and used. In such cases, the binding affinity and crystallization properties remain 
the same with smaller size and hybridization, which give enhanced tumor penetra-
tion. Also, modifications can be made to increase the specificity and valency of 
antibodies.
15. IgG formats
Involves changes in the structure of IgG to alter its natural properties to obtain 
desired attributes. The most common structural change includes changes in anti-
body binding region, e.g., ranibizumab. Right now, there are many fragment-based 
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therapeutics in preclinical and clinical trials. The most advanced is otlertuzumab 
for treating chronic lymphocytic leukemia. Fragment-based derivatives are not able 
to activate the immune system without a crystallization region [62]. But they show 
advantages like enhanced penetration, longer circulation and increased diffusion 
in the tumor. Hybrids can also be made with Fc from IgG and scFv from a targeting 
antibody. They do not penetrate in the tumor but instead retain activities of Fc such 
as immunization.
16. Multivalent binders
IgG can only bind a single type of antigen. Hence it is bivalent but not bispecific. 
Hence, to increase the specificity, the valency of antibodies is being enhanced. 
Many different regions from different sources are connected together to form 
molecules that are multivalent and can bind to more than one type of molecules.
16.1 Bispecific
This is the most used type from multispecific modified IgG. These can bind to 
two different antigens at once. For e.g., blinatumomab is used for some types of 
acute lymphocytic leukemia. It binds to CD19 protein on the cancer cell and CD3 
protein on T-cell. It causes the release of cytotoxic chemicals that kill the cancer cell. 
Dual affinity targeting agents are made from two separate light and heavy regions 
linked by disulfide bonds after translation.it can be stored for a long time and 
should be stable for a long time [63].
16.2 Multispecific and multivalent
A combination makes multivalent antibodies of three or more antibody domains 
joined sequentially or in a row. These are proteins specific for two antigens contain-
ing two pairs of light and heavy variable regions connected in a single chain forming 
a polypeptide. By virtue of their multivalency, tandem Abs not only target tumors 
but also cause infiltration and destruction of tumors by killer T-cells. These have 
longer storage life, better pharmacokinetics, are highly potent [64].
17. Antibody conjugates and fusion
Antibodies can be linked with other molecules such as proteins and peptides to 
form hybrids. Such combinations give altered biodistribution by targeting a dif-
ferent receptor, extend the half-life of formulation, or impart a new mechanism of 
action [65].
18. Antibody-drug conjugates
These hybrid molecules contain antibodies linked to a therapeutic agent. They 
combine the selective nature of antibodies with cytotoxicity of active agents [66]. 
It can reduce side effects to a minimum and shows maximum therapeutic success. 
Conjugates such as Mylotarg have been approved by the FDA. This has caused the 
emergence of many compounds that differ just by changing the method and site 
of conjugation. The drugs or linkers are attached to free lysine or cysteine, which 
gives different products based on the location of conjugation. The most recent trend 
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Figure 3. 
Types of antibody fragments.
involves forming a homogenous product by conjugation at particular sites only. 
It can be done by altering the structure of antibodies to incorporate non-natural 
amino acids, which act as a handle for attachment. Available tags have been discov-
ered, such as sortase A tag, which attaches the drug to antibody at the glutamic acid 
site and attaches to therapeutic moiety through a polyglycine tag.
19. Antibody-fusion constructs
These are molecules synthesized using recombinant DNA technology. They 
combine targeting efficiency of IgG and various protein domains. This fusion 
affects selectivity and PK parameters extensively. Toxic proteins can be used to 
form immunotoxic compounds such as diphtheria toxin attached to antibodies. 
Dose-limiting toxicity and immunogenicity are the main challenges in the forma-
tion of such complexes. The most successful examples of protein fusion complex are 
13
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bioactive proteins attached to the crystallization region of IgG. Amevive and zaltrap 
are two such complexes approved by USFDA for release in the market. This combi-
nation shows an excellent immune response against the tumor [67].
Types of antibody fragments: Deferent type of antibody fragments are men-
tioned in Figure 3.
20. Conclusion
There is no single magic remedy that acts against all of the diseases. Antibodies 
are ingenious proteins targeted toward specific foreign molecules inside the body. 
Their therapeutic use involves their ability to disrupt signal transduction, block 
receptor, which further affects cell growth and cell death. They also can be used 
to stimulate the immune system so as to destroy any foreign or ingenious harmful 
materials. IgG’s natural structure can be modified to remove problematic residues 
and add newly modified proteins for the purpose of targeting and immunostimulat-
ing. These attachments come with issues like immunogenicity, acquired resistance. 
But more research in field of antibody engineering is required to address this issue.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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